Thyroid nodule
Also known as: thyroid cancer · thyroid mass
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
American Thyroid Association (ATA) · 2015
The ATA guideline covers the evaluation of thyroid nodules and the management of differentiated thyroid cancer in adults; a separate 2025 ATA update addresses the cancer portion only.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
European Thyroid Association (ETA) · 2023
The ETA guideline describes a risk-adapted pathway for adults with thyroid nodules, from initial workup through ultrasound risk stratification, cytology and molecular testing to surveillance or intervention.
US vs EU key differences
- Risk-stratification tools differ: the ATA 2015 guideline uses its own five-tier sonographic pattern system, while the ETA 2023 guideline names EU-TIRADS the preferred system in Europe. source
- Biopsy size thresholds are more conservative in Europe: the ETA triggers fine-needle aspiration at >20 mm for EU-TIRADS 3 and >15 mm for EU-TIRADS 4, versus ATA cutoffs of ≥1.5 cm for low-suspicion and ≥1 cm for intermediate-suspicion nodules; both bodies aspirate high-risk nodules above 10 mm. source
- Molecular testing is treated differently: the ATA devotes several recommendations to molecular panels for Bethesda III/IV cytology, whereas the ETA says such testing may only be considered where available and flags limited validation and overtreatment risk outside the USA. source
- Version currency differs: the US guideline dates to 2015 and bundles nodules together with differentiated thyroid cancer, while the 2023 European guideline is a standalone, more recent thyroid-nodule document. source
What changed recently
- US2009 → 20152015-01-01
The 2015 ATA guidelines revised the 2009 edition, introducing sonographic pattern-based risk categories that set size thresholds for fine-needle aspiration so that many nodules under 1 cm no longer warrant biopsy, and adding guidance on molecular marker testing for indeterminate cytology. Overall management shifted toward risk-adapted, less aggressive care to limit overdiagnosis and overtreatment.
See the full update feed for changes across every system.